Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Recruiting
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Investigative Site US086, Birmingham, Alabama +341 locations
Conditions: Hidradenitis Suppurativa (HS)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Recruiting
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/30/2025
Locations: Sansum Clinic, Santa Barbara, California +370 locations
Conditions: Non-Small Cell Lung Cancer (NSCLC)
Combined Pulsed Field and Radiofrequency Energy for Ablation of Ventricular Tachycardia
Recruiting
This will be a single arm study evaluating a new ablation technology for performing catheter ablation of ventricular tachycardia. The technology combines novel pulsed field ablation with radiofrequency ablation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: McGill University Health Centre, Montreal, Quebec +2 locations
Conditions: Ventricular Tachycardia (V-Tach)
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone fo... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/30/2025
Locations: Digestive Health Specialsits, Dothan, Alabama +49 locations
Conditions: Ulcerative Colitis
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
Recruiting
The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: LA Universal Research Center, Inc., Los Angeles, California +261 locations
Conditions: Severe Hypertriglyceridemia
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Recruiting
Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1. To evaluate the effect of dazodalibep on patient-reported outcomes (PROs) in participants with SS. 2. To evaluate the effect of dazodalibep on measures of systemic activity, PROs, and salivary flow in participants with SS 3. To evaluate the safety and tolerability of multiple doses of dazodalibep in participants with SS
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Arizona Research Clinic PLLC, Chandler, Arizona +204 locations
Conditions: Sjögren's Syndrome (SS)
COgnitioN With VERiciGuat Evaluation in Heart Failure
Recruiting
CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Calgary, Calgary, Alberta +3 locations
Conditions: Heart Failure, Cognitive Impairment
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Recruiting
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +34 locations
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Recruiting
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week... Read More
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
07/30/2025
Locations: Digestive Health Specialists ( Site 5064), Dothan, Alabama +413 locations
Conditions: Crohn's Disease
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/30/2025
Locations: Investigative Site US257, Birmingham, Alabama +111 locations
Conditions: Hidradenitis Suppurativa
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Recruiting
The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the M... Read More
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
07/30/2025
Locations: Digestive Health Specialists ( Site 0135), Dothan, Alabama +450 locations
Conditions: Ulcerative Colitis
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/30/2025
Locations: Investigative Site US020, Phoenix, Arizona +108 locations
Conditions: Hidradenitis Suppurativa